Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysplasix for High-Risk HPV with ASC-US or LSIL
NCT07572396Phase 2Recruiting
- Sponsor
- Amplexd Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human papillomavirus infection and cervical dysplasia (CIN) (2 arms), sponsored by Amplexd Therapeutics. Primary endpoints: Safety and tolerability of Dysplasix intravaginal suppository therapy at Day 50, Regression of cervical cytology present at study entry at Day 50 and 1 more. Started Apr 2026; status: recruiting.
02
Conditions
human papillomavirus infectioncervical dysplasia (CIN)
Beyond the preview
Go deeper on NCT07572396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572396.